Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.
OBJECTIVE
Both natriuretic peptides and nitric oxide may be protective in cardiac hypertrophy, although their functional effects are diminished in hypertrophy. Hypoxia inducible factor-1 (HIF-1) may also protect in cardiac hypertrophy. We hypothesized that upregulation of HIF-1 would protect the functional effects of cyclic GMP (cGMP) signaling in hypertrophied ventricular myocytes.


METHODS
A cardiac hypertrophy model was created in mice by transverse aorta constriction. HIF-1 was increased by deferoxamine (150 mg/kg for 2 days). HIF-1alpha protein levels were examined. Functional parameters were measured (edge detector) on freshly isolated myocytes at baseline and after BNP (brain natriuretic peptide, 10(-8)-10(-7)M) or CNP (C-type natriuretic peptide, 10(-8)-10(-7)M) or SNAP (S-nitroso-N-acetyl-penicillamine, a nitric oxide donor, 10(-6)-10(-5)M) followed by KT5823 (a cyclic GMP-dependent protein kinase (PKG) inhibitor, 10(-6)M). We also determined PKG expression levels and kinase activity.


RESULTS
We found that under control conditions, BNP (-24%), CNP (-22%) and SNAP (-23%) reduced myocyte shortening, while KT5823 partially restored function. Deferoxamine treated control myocytes responded similarly. Baseline function was reduced in the myocytes from hypertrophied heart. BNP, CNP, SNAP and KT5823 also had no significant effects on function in these myocytes. Deferoxamine restored the negative functional effects of BNP (-22%), CNP (-18%) and SNAP (-19%) in hypertrophic cardiac myocytes and KT5823 partially reversed this effect. Additionally, deferoxamine maintained PKG expression levels and activity in hypertrophied heart.


CONCLUSIONS
Our results indicated that the HIF-1 protected the functional effects of cGMP signaling in cardiac hypertrophy through preservation of PKG.
Tan
Tao
T
Heart and Brain Circulation Laboratory, Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane West, Piscataway, NJ 08854-5635, USA.
Scholz
Peter M
PM
Weiss
Harvey R
HR
D000818:Animals; D002227:Carbazoles / Q000008:administration & dosage; D006332:Cardiomegaly / Q000503:physiopathology*; D006152:Cyclic GMP / Q000378:metabolism*; D017869:Cyclic GMP-Dependent Protein Kinases / Q000378:metabolism; D003676:Deferoxamine / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics / Q000378:metabolism*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D032383:Myocytes, Cardiac / Q000378:metabolism / Q000473:pathology*; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage / Q000378:metabolism; D020098:Natriuretic Peptide, C-Type / Q000008:administration & dosage / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D026423:S-Nitroso-N-Acetylpenicillamine / Q000494:pharmacology; D015398:Signal Transduction; D015854:Up-Regulation
D002227:Carbazoles; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D020097:Natriuretic Peptide, Brain; C073601:KT 5823; D020098:Natriuretic Peptide, C-Type; D009569:Nitric Oxide; D026423:S-Nitroso-N-Acetylpenicillamine; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP; D003676:Deferoxamine
Curr Treat Options Cardiovasc Med. 2007 Aug;9(4):289-301
17761114
J Surg Res. 2006 Sep;135(1):38-44
16600302
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1367-73
15550520
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H901-8
18083903
J Biomed Sci. 2005;12(2):409-20
15942707
Cardiovasc Res. 1999 Mar;41(3):514-23
10435023
J Surg Res. 2006 Aug;134(2):300-6
16545395
Science. 2003 Dec 12;302(5652):1975-8
14671307
Mol Pharmacol. 2006 Jun;69(6):1773-8
16567545
J Exp Med. 2007 Mar 19;204(3):657-66
17339407
J Biol Chem. 2001 Oct 26;276(43):39805-11
11514583
Cell Physiol Biochem. 2007;20(1-4):157-66
17595525
Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1251-7
16100251
Circ Res. 2007 Jun 8;100(11):1569-78
17556670
Pharmacol Ther. 2004 Jun;102(3):223-41
15246247
Curr Opin Genet Dev. 2004 Feb;14(1):81-5
15108809
Curr Heart Fail Rep. 2004 Dec;1(4):183-9
16036043
Pharmacol Rev. 2000 Sep;52(3):375-414
10977868
Biochem J. 2008 Jan 1;409(1):233-42
17822384
FEBS Lett. 2004 Oct 22;576(3):369-74
15498565
Circ Res. 2006 Jan 6;98(1):10-1
16397152
Neurol Res. 2008 Apr;30(3):288-93
17767813
Nature. 2007 Mar 22;446(7134):444-8
17334357
J Physiol. 2002 Jun 1;541(Pt 2):351-66
12042344
Cell Physiol Biochem. 2008;21(5-6):421-8
18453749
Hypertension. 2005 Dec;46(6):1355-61
16286571
Peptides. 2006 Sep;27(9):2276-83
16762459
Cardiovasc Hematol Agents Med Chem. 2006 Jul;4(3):189-97
16842205
J Appl Physiol (1985). 2000 Apr;88(4):1474-80
10749844
J Am Coll Cardiol. 2006 Aug 1;48(3):506-7
16875976
Circulation. 2003 Jul 8;108(1):79-85
12796124
J Biol Chem. 1999 Mar 26;274(13):9038-44
10085152
J Cardiovasc Pharmacol. 2007 Feb;49(2):100-5
17312451
Circ Res. 2002 Feb 8;90(2):E25-33
11834720
J Appl Physiol (1985). 2004 Mar;96(3):1173-7; discussion 1170-2
14766767
Trends Mol Med. 2001 Aug;7(8):345-50
11516994
Rev Esp Cardiol. 2006 May;59(5):473-86
16750145
Hypertension. 2009 Jan;53(1):49-56
19001185
Biochem Biophys Res Commun. 2002 Aug 30;296(4):976-82
12200144
Cardiovasc Res. 2003 Nov 1;60(2):268-77
14613856
Life Sci. 2007 Aug 16;81(10):779-93
17707439
Int J Biochem Cell Biol. 2005 Mar;37(3):535-40
15618010
Nature. 2000 Mar 9;404(6774):197-201
10724174